Dr. Mirza on Safety Profile of Niraparib/Bevacizumab in Recurrent Ovarian Cancer

Video

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Mansoor Raza Mirza, MD, medical director of the Nordic Society of Gynaecologic Oncology-Clinical Trial Unit and chief oncologist within the Department of Oncology in Rigshospitalet, Copenhagen University Hospital, discusses the safety ​profile of niraparib (Zejula) in combination with bevacizumab (Avastin) in platinum-sensitive recurrent ovarian cancer.

During the 2020 ASCO Virtual Scientific Program, final analysis of the phase 3 NSGO-AVANOVA2/ENGOT-OV24 trialdemonstrated continued, statistically significant activity with the combination compared with niraparib alone in this patient population.

Notably, no new safety signals were observed with the regimen, says Mirza. Some patients experienced adverse effects such as hypertension and proteinuria, but they were not unexpected in this setting.

Moreover, no deterioration in quality of life according to patient-reported outcomes ​was reported with the combination versus niraparib alone, Mirza concludes.

Related Videos
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD
Kari Wisinski, MD, Endowed Professor of Hematology and Oncology, chief, Division of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin (UW) School of Medicine and Public Health; associate director, Clinical Research, co-lead, Breast Cancer Disease Oriented Team, UW Carbone Cancer Center
Susan C. Modesitt, MD, FACOG, FACS, professor, Department of Gynecology and Obstetrics, director, Division of Gynecologic Oncology, Department of Gynecology and Obstetrics, Emory University School of Medicine
Nikhil A. Gopal, MD
Hans C. Lee, MD
Manish A. Shah, MD
Jobelle Baldonado, MD
Alexey Danilov, MD, PhD,